argenx SE (ARGX) stock: Winston Score and insider trades

argenx SE is a biotechnology company that develops medicines for rare and serious diseases caused by a malfunctioning immune system. Its main product is Vyvgart (efgartigimod), a drug that treats conditions where the body's own antibodies attack healthy tissue. The company focuses on diseases like myasthenia gravis and immune thrombocytopenia, selling primarily to hospitals and specialty clinics. argenx earns money by selling Vyvgart in multiple forms — an intravenous infusion and a self-injectable version — across the United States, Europe, Japan, and other markets. The company is headquartered in the Netherlands but operates globally, and its high gross margin reflects the premium pricing typical of rare-disease drugs. Its key competitive advantage is a proprietary antibody technology platform that can be applied to multiple diseases, but its main risk is heavy dependence on a single drug franchise, making future approvals in additional indications critical to sustaining growth.

Editorial rules set and reviewed by Felix Prehn, Economist and Editor. Figures are refreshed daily from Financial Modeling Prep and company filings; last refreshed 2026-10-14.